Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.

View Full Paper
Ask AI
Bookmark
Share

Authors

IDIvetta Danylesko

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows HSCT improves survival in myelofibrosis, suggesting ongoing risks after relapse.

Key Points

  • To evaluate long-term outcomes and relapse patterns after allogeneic HSCT in myelofibrosis patients.
  • Retrospective analysis of HSCT outcomes in myelofibrosis patients from 2002 to 2025.
  • Inclusion of patients with primary or secondary myelofibrosis, excluding those with Acute Myeloid Leukemia (AML).
  • Assessment of relapse types and survival rates over a median follow-up of 5.6 years.
  • Estimated 10-year overall survival (OS) is 48% with improvements noted in recent years.
  • Twenty-six patients relapsed after HSCT, with 5 and 10-year relapse rates of 22% and 31%, respectively.
  • Mortality rates identified significant non-relapse causes and differences based on relapse patterns.

Cite This Study

Ivetta Danylesko (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da23https://doi.org/10.1182/blood-2025-6054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study2025
  2. 2The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis2026
  3. 3Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis2024 · 6 citations
  4. 4Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025
  5. 5An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025